[Evaluation of the tolerance and efficiency of quinfamide, a new intraluminal amebicide, in man (one day treatment). Double blind study].
A new intraluminal amebicide (Quinfamide) was tested to assess its effectivity and tolerance for treatment of non-dysenteric intestinal amebiasis. The drug was administered to three groups of ten patients each, whom received 300, 600 and 1 200 mg. on a 24 hours schedule. Another group of ten patients received Teclozan as control drug. Diagnosis and results were judged by rectosigmoidoscopy before, 15 and 30 days after treatment. In addition, microscopic investigation of ameba was performed in freshly passed stools, before, and after 8, 15 and 30 days of treatment. Success after treatment with the three doses of Quinfamide was obtained in 89.2% of the cases. Side reactions were clinically non-significant. More experience is needed before the effectivity of the drug is stablished.
D000081:Acetamides / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000562:Amebiasis / Q000188:drug therapy*; D000563:Amebicides / Q000627:therapeutic use*; D000588:Amines / Q000627:therapeutic use*; D001596:Benzylamines / Q000627:therapeutic use*; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011804:Quinolines / Q000627:therapeutic use*
D000081:Acetamides; D000563:Amebicides; D000588:Amines; D001596:Benzylamines; D011804:Quinolines; C017951:teclozan; C026546:quinfamide
Evaluación de la tolerancia y eficacia en humanos de quinfamide un nuevo amebicida intraluminal (tratamiento de un día). Estudio doble ciego.